Scheduled Maintenance. MDBriefCase will be down on Sunday, November 27, 2022.
We are busy updating our website and learning platform to enhance your learning experience. We’ll be back up and running again before long, so please try again soon.

Recent literature demonstrates that lung cancer represents around 4% of cancers diagnosed cancers in the Kingdom of Saudi Arabia (KSA). It is the 4th most common cancer in men and the 17th most common cancer in women.

The objective of this online program is to help educate and support pharmacists in KSA in understanding the current landscape of lung cancer: genetic mutations, risk factors, and treatment approaches. The module reviews Saudi lung cancer management guidelines, discusses adverse events that may occur with treatment, and Saudi guidelines for the management of these adverse events.

This program has received an educational grant or in-kind support from Novartis.